Tempest Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-9.6M | $-7.9M | $-7.5M | $-6.8M | $-7.6M | $-7.6M | $-9.1M | $-8.9M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $155.0K | $88.0K | $85.0K | $88.0K | $83.0K | $125.0K | $217.0K | $201.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | $-5.5M | $-7.2M | $-6.2M | $-6.5M | $-6.4M | $-8.3M | $-6.5M | $-9.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $249.0K | $168.0K | $7.0K | $0 | $117.0K | $46.0K | $356.0K | $108.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-249.0K | $-168.0K | $-7.0K | $0 | $-117.0K | $-46.0K | $-356.0K | $-108.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $4.6M | $450.0K | $34.3M | $21.0K | $1.2M | $44.0K | $-4.7M | $350.0K |
| Net Change in Cash | — | — | — | $-6.5M | $-5.3M | $-8.3M | — | $-8.8M |
| Free Cash Flow | $-5.8M | $-7.4M | $-6.2M | $-6.5M | $-6.5M | $-8.3M | $-6.8M | $-9.2M |